Business Context and Reporting Period
This Form 8-K is filed by GlycoMimetics, Inc. (GLYC) on July 30, 2021, reporting events occurring between July 30 and August 5, 2021. The filing primarily addresses a significant change in executive leadership and references the company's financial results for the second quarter ended June 30, 2021, which were announced via a press release on August 5, 2021.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained in the press release furnished as Exhibit 99.1, which is incorporated by reference but not detailed within the body of this 8-K.
Material Changes and Executive Leadership
The most significant material change reported is the departure of the Chief Executive Officer and the appointment of a successor.
- CEO Retirement: Rachel K. King retired as President and CEO effective August 6, 2021. She remains an employee until August 31, 2021, and will continue to serve on the Board of Directors.
- Consulting Arrangement: Ms. King entered a consulting agreement through August 31, 2022, providing up to 20 hours of service per week for a monthly fee of $23,304.17. She forfeited the second half of a retention bonus originally scheduled for September 2021.
- New CEO Appointment: Harout Semerjian was appointed President and CEO effective August 6, 2021. He was also appointed to the Board of Directors, expanding the board size from seven to eight members.
Compensation, Equity, and Outlook
The filing details the compensation package for the new CEO, Harout Semerjian, and changes to the company's equity plans.
- Base Salary and Bonus: Mr. Semerjian receives an annual base salary of $595,000 and a sign-on bonus of $200,000 (paid in two installments). He is eligible for an annual target bonus of 55% of his base salary.
- Equity Grants: On August 3, 2021, Mr. Semerjian was granted options to purchase 1,647,600 shares of common stock at an exercise price of $2.03 per share.
- 1,098,400 shares vest 25% on August 3, 2022, with the remainder vesting monthly over 36 months.
- 549,200 shares are performance-based, vesting upon FDA approval of uproleselan and subsequent commercial sales.
- Severance Provisions: The employment agreement includes severance provisions for termination without cause or resignation for good reason, including 18 months of base salary continuation and potential acceleration of equity awards in the event of a Change in Control.
- Equity Plan Amendment: The Compensation Committee increased the shares reserved under the Inducement Plan from 500,000 to 2,000,000 shares to facilitate the CEO's equity grant.
Investor Verification Checklist
- Review Exhibit 99.1 (August 5, 2021 Press Release) for specific Q2 2021 financial results, including cash position and burn rate.
- Verify the status of the lead product candidate, uproleselan, particularly regarding FDA approval timelines referenced in the CEO's performance-based equity vesting.
- Confirm the total cash impact of the new CEO's sign-on bonus and the former CEO's consulting fees on the company's liquidity.
- Monitor the transition period to ensure operational continuity following the leadership change effective August 6, 2021.